Co-Authors
This is a "connection" page, showing publications co-authored by HOMER A MACAPINLAC and ERIC ROHREN.
Connection Strength
2.557
-
Spectrum of Benign Bone Conditions on NaF-PET. Semin Nucl Med. 2017 07; 47(4):392-396.
Score: 0.588
-
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12.
Score: 0.519
-
PET Imaging of Prostate Cancer: Other Tracers. PET Clin. 2009 Apr; 4(2):185-92.
Score: 0.337
-
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
Score: 0.167
-
Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience. Curr Radiopharm. 2018; 11(2):147-152.
Score: 0.154
-
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015 Aug; 56(8):1177-84.
Score: 0.129
-
Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):906-14.
Score: 0.117
-
Implementation of automated tube current modulation in PET/CT: prospective selection of a noise index and retrospective patient analysis to ensure image quality. J Nucl Med Technol. 2011 Jun; 39(2):83-90.
Score: 0.097
-
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open. 2019; 4(1):e000439.
Score: 0.042
-
Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy? Radiol Bras. 2019 Jan-Feb; 52(1):33-40.
Score: 0.041
-
Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017 Jun; 44(6):969-978.
Score: 0.036
-
Reply: Prediction vs. Prognostication and Guarantee-Time Bias: Steering Clear of the Pitfalls of Interpreting Observational Data. J Nucl Med. 2016 06; 57(6):991.
Score: 0.034
-
Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. 2016 Apr; 41(4):268-73.
Score: 0.034
-
Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016 Jan; 43(1):8-20.
Score: 0.033
-
What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies? Int J Mol Imaging. 2013; 2013:476786.
Score: 0.029
-
Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94.
Score: 0.023
-
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
Score: 0.023
-
Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44.
Score: 0.023
-
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8.
Score: 0.023
-
Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. J Appl Clin Med Phys. 2010 Feb 04; 11(1):3073.
Score: 0.022
-
The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92.
Score: 0.022
-
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11.
Score: 0.021
-
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009 Mar; 50(3):340-7.
Score: 0.021
-
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009 Feb; 50(2):231-8.
Score: 0.021